Merck & Co. Inc., of Whitehouse Station, N.J., said the pivotal phase III study (KEYNOTE-006) testing PD-1 inhibitor Keytruda (pembrolizumab) against Yervoy (ipilimumab, Bristol-Myers Squibb Co.) in the first-line treatment of patients with advanced melanoma met its two primary endpoints of progression-free survival and overall survival.